3 ms·
The sample size is 62 and the mortality rates are between 0% and 7% depending primarily on age and co-morbidities. I don't think we can draw any meaningful conc
by arcticbull 7y ago
The sample size is 62 and the mortality rates are between 0% and 7% depending primarily on age and co-morbidities. I don't think we can draw any meaningful conclusions from this other than what we already know: seems worth looking into HCQ more.
- marcosdumay 7y agoHow does the 2 cases of collateral effects compare to the normal consequences of the drug? It is very likely that we can draw conclusions about those.
- James_Henry 7y agoThe side effects were a headache and a rash, neither one serious. The worrisome side effects of HCQ are also given in the paper: "Retinopathy is one of the major adverse reactions of long-term therapy with HCQ. Besides, patients with rheumatoid diseases treated with HCQ occasionally experience arrhythmias." Luckily, long-term use of the drug isn't necessary here because the immune system successfully responds with antibodies to fight of the virus, so retinopathy isn't an issue. Also, as the paper states, "Fortunately, deciding on individual treatment plans scientifically, monitoring adverse reactions timely, to avoid overdose, short-term application of HCQ is relatively safe."
- marcosdumay 7y agoSo, evidence is pointing that we have a drug that drastically reduces hospitalization time for the milder cases, can save some 5-10% of the grave cases and is perfectly safe as long as there is a doctor looking at the patients. That is really looking like a large win. This is one of the drugs on the large study WHO is running worldwide, and is getting a lot of attention. I'm sure we'll have strong evidence either way soon.
- James_Henry 7y agoI don't know that this study is talking about reduced hospitalization times. In fact, mild cases don't end up in the hospital. However, it could be that mild cases end up turning into severe cases that need hospitalization less frequently if this treatment is used. Since hospitalization is only needed in some 20% of cases, it would probably take a larger study to meaningfully determine those effects. Of course, (and even though this probably isn't the case) if all this treatment does is make the mild and moderate cases (those without and with pneumonia and not needing supplemental oxygen) end faster, we can get to herd immunity that much quicker. And yes, people are using this drug and are going to be using this drug at an increasing rate, so we'll have plenty of evidence soon.
- James_Henry 7y agoThey weren't looking at the effects on mortality. They looked at TTCR ("the return of body temperature and cough relief, maintained for more than 72 h") and radiological changes. They found a decently large effect in both of these. The meaningful conclusion is "Considering that there is no better option at present, it is a promising practice to apply HCQ to COVID-19 under reasonable management."
- James_Henry 7y agoAlso, you don't need to decrease mortality to have a huge benefit from a treatment. If you just get people recovering faster, you've probably indirectly saved many lives!